PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
February 27, 2024Thoracic CancerOpen Access

Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective

View Full Paper
Ask AI
Bookmark
Share

Authors

FDFuqiang DaiCCCong ChenGZGuanyu Zhou

Discussion

Loading...

Member takes

Overview

Retrospective cohort study investigates prognosis following surgery versus maintenance therapy in stage III NSCLC, suggesting defined surgical pathways.

Key Points

  • Surgical intervention after favorable response to neoadjuvant chemoimmunotherapy may improve outcomes in advanced stage III NSCLC.
  • Prognostic comparisons evaluate post-induction surgery against continued immunotherapy and chemotherapy in advanced lung cancer.
  • Matched retrospective cohort study evaluates therapeutic outcomes across surgical and systemic maintenance cohorts in stage III NSCLC.

Cite This Study

Dai et al. (2024) studied this question.

synapsesocial.com/papers/68e77584b6db6435876ea8b3https://doi.org/10.1111/1759-7714.15247
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment2024 · 2 citations
  2. 2Preliminary experience of surgery after neoadjuvant immunotherapy combined with chemotherapy for stage-IIIB non-small cell lung cancer2024 · 1 citations
  3. 3A case report of cStage IIIB squamous cell lung carcinoma completely resected after downstaging with neoadjuvant therapy2024 · 1 citations
  4. 4Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses2025 · 15 citations
  5. 5Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study2024 · 2 citations